Breaking News

Alstom to Pay Record $772 Million in U.S. Bribery Settlement
Tweet TWEET

Amarin Announces Submission of Supplemental New Drug Application for Chemport, Inc. as an Additional Vascepa(R) Active

Amarin Announces Submission of Supplemental New Drug Application for Chemport,
Inc. as an Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier

BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today the submission of a Supplemental New Drug Application
(sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for
Chemport, Inc. as an additional Vascepa^® (icosapent ethyl) active
pharmaceutical ingredient (API) supplier.

"A key goal of Amarin is to expand our global supply chain to support expected
Vascepa demand, diversify our supply base and ensure cost-efficient supply,"
stated Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "The
sNDA submission for Chemport is an important step toward achieving this goal."

This submission contributes to the planned expansion of the Vascepa
manufacturing supply chain and is additional progress toward Amarin's goal to
protect the commercial potential of Vascepa to beyond 2030 through a
combination of patent protection, regulatory exclusivity, trade secrets and by
taking advantage of manufacturing barriers to entry. Along with this expansion
in supply, Amarin's significant progress includes expansion of patent
protection for Vascepa in the United States with 11 Amarin patents either
issued or allowed and over 30 additional patent applications being prosecuted.
Amarin is also pursuing patent applications related to Vascepa in multiple
jurisdictions outside the United States.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

Forward-looking statements

This press release contains forward-looking statements, including statements
about the manufacturing capacity and qualification of Vascepa suppliers and
the timing and likelihood of regulatory approvals, the timing of commercial
launch of Vascepa and Amarin's plan to protect the commercial potential of
Vascepa. These forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. Among the factors that could
cause actual results to differ materially from those described or projected
herein include uncertainties associated generally with research and
development, clinical trials and related regulatory submissions and approvals.
A further list and description of these risks, uncertainties and other risks
associated with an investment in Amarin can be found in Amarin's filings with
the U.S. Securities and Exchange Commission, including its most recent
Quarterly Report on Form 10-Q. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Amarin undertakes no obligation to
update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise.

CONTACT: Amarin contact information:
         Stephen D. Schultz
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.